Cftr Trikafta denied as non-formulary by Aetna?

Aetna's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Trikafta as Non-Formulary

A non-formulary denial means Trikafta does not appear on Aetna's covered drug list for your specific plan tier, or appears only on a specialty tier requiring separate authorization. This is a coverage-design issue, not a clinical judgment—but it is still fully appealable, particularly when no reasonable formulary alternative exists for your CF genotype.

The central argument in a non-formulary appeal is that the formulary alternatives (if any exist) are clinically inappropriate for your specific mutation, and that access to Trikafta is medically necessary for your specific case. A formulary exception can grant coverage at an in-formulary cost tier.

## Your Federal Appeal Rights

• Formulary exception request: Most plans must offer a formulary exception process. Submit simultaneously with or before the formal appeal. Your prescriber must attest that no formulary alternative is appropriate.
• Internal appeal: File within the deadline on the denial notice. Under ACA rules, the plan must decide urgent appeals quickly and standard pre-service appeals within 30 days.
• External review (ACA §2719): If the internal appeal is denied, you may request independent external review within approximately 4 months of the final denial. External reviewers evaluate whether the plan's application of its formulary rules was consistent with generally accepted medical practice.
• ERISA §503 (self-funded plans): Entitles you to the plan's formulary management criteria and all documents used in the decision.

## Documentation to Gather

1. Genetic mutation report: Demonstrates why your specific mutation profile requires Trikafta specifically and why formulary alternatives (if listed) are not approved for your genotype. 2. Prescriber formulary-exception letter: The prescriber should explain, mutation by mutation, why each listed formulary alternative is either not indicated for this patient or was tried and failed, and why Trikafta is the only clinically appropriate option. 3. FDA label comparison: Pull the approved indications for both Trikafta and any formulary alternative Aetna lists. A side-by-side showing your patient's mutation falls outside the alternative's label is powerful evidence. 4. Clinical status notes: Recent pulmonary function data and clinical course to establish the urgency and severity of unmet need.

## Criteria-Mapping Structure

| Non-Formulary Exception Criterion | Your Evidence | |---|---| | No formulary alternative approved for this genotype | FDA label excerpts for each alternative | | Patient tried and failed formulary alternatives (if applicable) | Treatment history with dates and outcomes | | Medical necessity of Trikafta specifically | Prescriber letter with genotype rationale | | Clinical severity and risk without access | Recent spirometry + specialist notes |

Request Aetna's current formulary and exception criteria in writing. If the plan's formulary was last updated before the FDA expanded Trikafta's approved population to include your patient's mutation class, note that discrepancy explicitly in your appeal.